↓ Skip to main content

Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus

Overview of attention for article published in Current Pharmaceutical Design, March 2018
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
59 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus
Published in
Current Pharmaceutical Design, March 2018
DOI 10.2174/1381612823666171109112307
Pubmed ID
Authors

Sayed Sartaj Sohrab, Sherif Aly El-Kafrawy, Zeenat Mirza, Mohammad Amjad Kamal, Esam Ibraheem Azhar

Abstract

The MERS-CoV is a novel human coronavirus causing respiratory syndrome since April 2012. The replication of MERS-CoV is mediated by ORF 1ab and viral gene activity can be modulated by RNAi approach. The inhibition of virus replication has been documented in cell culture against multiple viruses by RNAi approach. Currently, very few siRNA against MERS-CoV have been computationally designed and published. In this review, we have discussed the computationally designing and delivery of potential siRNAs. Potential siRNA can be designed to silence a desired gene by considering many factors like target site, specificity, length and nucleotide content of siRNA, removal of potential off-target sites, toxicity and immunogenic responses. The efficient delivery of siRNAs into targeted cells faces many challenges like enzymatic degradation and quick clearance through renal system. The siRNA can be delivered using transfection, electroporation and viral gene transfer. Currently, siRNAs delivery has been improved by using advanced nanotechnology like lipid nanoparticles, inorganic nanoparticles and polymeric nanoparticles. The efficacy of siRNA-based therapeutics has been used not only against many viral diseases but also against non-viral diseases, cancer, dominant genetic disorders, and autoimmune disease. This innovative technology has attracted researchers, academia and pharmaceuticals industries towards designing and development of highly effective and targeted disease therapy. By using this technology, an effective and potential siRNAs can be designed, delivered and their efficacy with toxic effects and immunogenic responses can be tested against MERS-CoV.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 59 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 24%
Student > Bachelor 7 12%
Student > Master 7 12%
Professor 5 8%
Professor > Associate Professor 5 8%
Other 10 17%
Unknown 11 19%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 13 22%
Medicine and Dentistry 5 8%
Agricultural and Biological Sciences 3 5%
Nursing and Health Professions 2 3%
Veterinary Science and Veterinary Medicine 2 3%
Other 12 20%
Unknown 22 37%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 November 2017.
All research outputs
#13,119,494
of 16,506,249 outputs
Outputs from Current Pharmaceutical Design
#2,194
of 3,043 outputs
Outputs of similar age
#239,810
of 324,831 outputs
Outputs of similar age from Current Pharmaceutical Design
#24
of 39 outputs
Altmetric has tracked 16,506,249 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,043 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 17th percentile – i.e., 17% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,831 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.